Lunai Bioworks Inc. (LNAI)
NASDAQ: LNAI · Real-Time Price · USD
0.3327
-0.0071 (-2.09%)
At close: Apr 29, 2026, 4:00 PM EDT
0.3105
-0.0222 (-6.67%)
After-hours: Apr 29, 2026, 7:58 PM EDT
Lunai Bioworks Employees
Lunai Bioworks had 29 employees as of June 30, 2025. The number of employees increased by 4 or 16.00% compared to the previous year.
Employees
29
Change (1Y)
4
Growth (1Y)
16.00%
Revenue / Employee
n/a
Profits / Employee
-$4,328,395
Market Cap
12.07M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 29 | 4 | 16.00% |
| Jun 30, 2024 | 25 | 13 | 108.33% |
| Jun 30, 2023 | 12 | -10 | -45.45% |
| Jun 30, 2022 | 22 | 11 | 100.00% |
| Jun 30, 2021 | 11 | 1 | 10.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioCardia | 21 |
| Moleculin Biotech | 17 |
| Reviva Pharmaceuticals Holdings | 14 |
| BioVie | 13 |
| Cellectar Biosciences | 11 |
| Traws Pharma | 7 |
| Intensity Therapeutics | 7 |
| Jupiter Neurosciences | 5 |
LNAI News
- 14 days ago - Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships - PRNewsWire
- 22 days ago - Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion - PRNewsWire
- 4 weeks ago - Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications - PRNewsWire
- 5 weeks ago - Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model - PRNewsWire
- 2 months ago - Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping - PRNewsWire
- 2 months ago - Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC - PRNewsWire
- 2 months ago - Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - PRNewsWire
- 3 months ago - Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - PRNewsWire